Cargando…

Prognostic impact of presumed breast or ovarian cancer among patients with unfavorable-subset cancer of unknown primary site

BACKGROUND: The clinical utility and prognostic impact of presumed primary breast or ovarian cancer among patients with an unfavorable subset of cancer of unknown primary site (CUP) remains unclear. We aimed to evaluate the clinical relevance of the presumed primary site of CUP and the clinical outc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kodaira, Makoto, Yonemori, Kan, Shimoi, Tatsunori, Yoshida, Akihiko, Yoshida, Masayuki, Kitano, Atsuko, Shimomura, Akihiko, Yunokawa, Mayu, Shimizu, Chikako, Takiguchi, Yuichi, Fujiwara, Yasuhiro, Tamura, Kenji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5809895/ https://www.ncbi.nlm.nih.gov/pubmed/29433539 http://dx.doi.org/10.1186/s12885-018-4092-4

Ejemplares similares

The Incidence of Nonmalignant Diseases among Patients with Suspected Carcinoma of Unknown Primary Site
por: Sato, Jun, et al.
Publicado: (2019)

Tumour-infiltrating lymphocytes are correlated with higher expression levels of PD-1 and PD-L1 in early breast cancer
por: Kitano, Atsuko, et al.
Publicado: (2017)

Prolonged Hypocalcemia Following a Single Dose of Denosumab for Diffuse Bone Metastasis of Gastric Cancer after Total Gastrectomy
por: Iizumi, Sakura, et al.
Publicado: (2017)

Efficacy and safety of eribulin in patients with locally advanced or metastatic breast cancer not meeting trial eligibility criteria: a retrospective study
por: Iizumi, Sakura, et al.
Publicado: (2017)

Hotspot mutation profiles of AKT1 in Asian women with breast and endometrial cancers
por: Shimoi, Tatsunori, et al.
Publicado: (2021)

TERT promoter hotspot mutations in breast cancer
por: Shimoi, Tatsunori, et al.
Publicado: (2017)

PIK3CA mutation profiling in patients with breast cancer, using a highly sensitive detection system
por: Shimoi, Tatsunori, et al.
Publicado: (2018)

Diagnostic value of tumor markers in identifying favorable or unfavorable subsets in patients with cancer of unknown primary: a retrospective study
por: Takamizawa, Shigemasa, et al.
Publicado: (2022)

Efficacy of capecitabine in patients with locally advanced or metastatic breast cancer with or without prior treatment with fluoropyrimidine: a retrospective study
por: Iizumi, Sakura, et al.
Publicado: (2018)

Phase I study of taselisib in Japanese patients with advanced solid tumors or hormone receptor‐positive advanced breast cancer
por: Tamura, Kenji, et al.
Publicado: (2018)

Comparison of the efficacy of trastuzumab emtansine between patients with metastatic human epidermal growth factor receptor 2-positive breast cancers previously treated with combination trastuzumab and pertuzumab and with trastuzumab only in Japanese population
por: Noda-Narita, Shoko, et al.
Publicado: (2019)

Pathological features of triple‐negative breast cancers that showed progressive disease during neoadjuvant chemotherapy
por: Tanabe, Yuko, et al.
Publicado: (2017)

Phase 1 dose‐escalation study of single‐agent veliparib in Japanese patients with advanced solid tumors
por: Nishikawa, Tadaaki, et al.
Publicado: (2017)

Taxane-induced sensory peripheral neuropathy is associated with an SCN9A single nucleotide polymorphism in Japanese patients
por: Tanabe, Yuko, et al.
Publicado: (2020)

Content Analysis of Oncology-Related Pharmaceutical Advertising in a Peer-Reviewed Medical Journal
por: Yonemori, Kan, et al.
Publicado: (2012)

Visualization of the distribution of nanoparticle-formulated AZD2811 in mouse tumor model using matrix-assisted laser desorption ionization mass spectrometry imaging
por: Ryu, Shoraku, et al.
Publicado: (2020)

Neoadjuvant chemotherapy promotes the expression of HER3 in patients with ovarian cancer
por: Mizuno, Takaaki, et al.
Publicado: (2020)

(64)Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients
por: Kurihara, Hiroaki, et al.
Publicado: (2015)

Survival outcomes in patients with human epidermal growth factor receptor 2 positive metastatic breast cancer administered a therapy following trastuzumab emtansine treatment
por: Watanuki, Rurina, et al.
Publicado: (2020)

Durable response of chemotherapy for cancer of unknown primary with unfavorable subset developed in retroperitoneal space
por: Matsukawa, Atsuki, et al.
Publicado: (2021)

Case Report: Successful Immunotherapy Improved the Prognosis of the Unfavorable Subset of Cancer of Unknown Primary
por: Mei, Jie, et al.
Publicado: (2022)

First‐in‐human study of the cancer peptide vaccine TAS0313 in patients with advanced solid tumors
por: Kondo, Shunsuke, et al.
Publicado: (2021)

Primary Yolk Sac Tumor of the Omentum: A Case Report and Literature Review
por: Harano, Kenichi, et al.
Publicado: (2012)

Breast Cancer Brain Metastasis—Overview of Disease State, Treatment Options and Future Perspectives
por: Watase, Chikashi, et al.
Publicado: (2021)

HER3 protein expression as a risk factor for post-operative recurrence in patients with early-stage adenocarcinoma and adenosquamous carcinoma of the cervix
por: Mizuno, Takaaki, et al.
Publicado: (2020)

Irinotecan plus carboplatin for patients with carcinoma of unknown primary site
por: Yonemori, K, et al.
Publicado: (2009)

Response to Dabrafenib and Trametinib of a Patient with Metaplastic Breast Carcinoma Harboring a BRAF V600E Mutation
por: Seo, Takuji, et al.
Publicado: (2020)

Gene Alterations in Triple-Negative Breast Cancer Patients in a Phase I/II Study of Eribulin and Olaparib Combination Therapy
por: Shimomura, Akihiko, et al.
Publicado: (2019)

Clinical and microarray analysis of breast cancers of all subtypes from two prospective preoperative chemotherapy studies
por: Okuma, H S, et al.
Publicado: (2016)

Impact of adjuvant chemotherapy and radiotherapy on tumour-infiltrating lymphocytes and PD-L1 expression in metastatic breast cancer
por: Yazaki, Shu, et al.
Publicado: (2022)

Travel Time and Distance and Participation in Precision Oncology Trials at the National Cancer Center Hospital
por: Uehara, Yuji, et al.
Publicado: (2023)

First‐in‐human study of ONO‐4578, an antagonist of prostaglandin E(2) receptor 4, alone and with nivolumab in solid tumors
por: Iwasa, Satoru, et al.
Publicado: (2022)

Integrative prognostic analysis of tumor–infiltrating lymphocytes, CD8, CD20, programmed cell death-ligand 1, and tertiary lymphoid structures in patients with early-stage triple-negative breast cancer who did not receive adjuvant chemotherapy
por: Yazaki, Shu, et al.
Publicado: (2022)

Low HER2 expression is a predictor of poor prognosis in stage I triple-negative breast cancer
por: Sanomachi, Tomomi, et al.
Publicado: (2023)

Treatable Subsets in Cancer of Unknown Primary Origin
por: Sumi, Hajime, et al.
Publicado: (2001)

Phase I study of the indoleamine 2,3-dioxygenase 1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with the PD-L1 inhibitor atezolizumab in Japanese patients with advanced solid tumours
por: Ebata, Takahiro, et al.
Publicado: (2019)

Impact of ALK Inhibitors in Patients With ALK-Rearranged Nonlung Solid Tumors
por: Takeyasu, Yuki, et al.
Publicado: (2021)

Do all patients in the phase I oncology trials need to be hospitalized? Domestic but outstanding issues for globalization of drug development in Japan
por: Shimomura, Akihiko, et al.
Publicado: (2017)

High mesothelin expression is correlated with non-squamous cell histology and poor survival in cervical cancer: a retrospective study
por: Takamizawa, Shigemasa, et al.
Publicado: (2022)

Lymphocyte-to-monocyte ratio as a prognostic and potential tumor microenvironment indicator in advanced soft tissue sarcoma treated with first-line doxorubicin therapy
por: Watanabe, Sho, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_t9876sml8k0tcff95ldgdkk73d